Finally, we further tested the ability of DYRK1A inhibition to enhance and promote cancer cells response to chemotherapy treatment, in more clinically relevant settings, using an in vivo colon cancer and TNBC xenograft transplantation models. This evidence concerns the gene DYRK1A and malignant colon neoplasm.